|
LM_ID
|
Common Name
|
Systematic Name
|
Main class
|
Sub class
|
Mass
|
Formula
|
|
LMFA04010363
|
ent-17-E4t-NeuroP
|
(4Z,7Z)-9-((1R,2S,3S)-3-hydroxy-2-((R,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-5-oxocyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010242
|
ent-17-epi-17-D4t-NeuroP
|
(4Z,7Z)-9-((1S,2R,5R)-5-hydroxy-2-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-3-oxocyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010239
|
ent-17-epi-17-D4t-NeuroP
|
(4Z,7Z)-9-((1R,2S,5R)-5-hydroxy-2-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-3-oxocyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010367
|
ent-17-epi-17-E4t-NeuroP
|
(4Z,7Z)-9-((1R,2S,3S)-3-hydroxy-2-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-5-oxocyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010370
|
ent-17-epi-17-E4t-NeuroP
|
(4Z,7Z)-9-((1S,2R,3S)-3-hydroxy-2-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-5-oxocyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010254
|
ent-20-D4c-NeuroP
|
(4Z,7Z,10Z)-12-((1S,2R,5R)-5-hydroxy-2-((R,E)-3-hydroxypent-1-en-1-yl)-3-oxocyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010251
|
ent-20-D4t-NeuroP
|
(4Z,7Z,10Z)-12-((1R,2S,5R)-5-hydroxy-2-((R,E)-3-hydroxypent-1-en-1-yl)-3-oxocyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010382
|
ent-20-E4c-NeuroP
|
(4Z,7Z,10Z)-12-((1S,2R,3S)-3-hydroxy-2-((R,E)-3-hydroxypent-1-en-1-yl)-5-oxocyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010379
|
ent-20-E4t-NeuroP
|
(4Z,7Z,10Z)-12-((1R,2S,3S)-3-hydroxy-2-((R,E)-3-hydroxypent-1-en-1-yl)-5-oxocyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010255
|
ent-20-epi-20-D4t-NeuroP
|
(4Z,7Z,10Z)-12-((1R,2S,5R)-5-hydroxy-2-((S,E)-3-hydroxypent-1-en-1-yl)-3-oxocyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010258
|
ent-20-epi-20-D4t-NeuroP
|
(4Z,7Z,10Z)-12-((1S,2R,5R)-5-hydroxy-2-((S,E)-3-hydroxypent-1-en-1-yl)-3-oxocyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010383
|
ent-20-epi-20-E4t-NeuroP
|
(4Z,7Z,10Z)-12-((1R,2S,3S)-3-hydroxy-2-((S,E)-3-hydroxypent-1-en-1-yl)-5-oxocyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010386
|
ent-20-epi-20-E4t-NeuroP
|
(4Z,7Z,10Z)-12-((1S,2R,3S)-3-hydroxy-2-((S,E)-3-hydroxypent-1-en-1-yl)-5-oxocyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010196
|
ent-4,11-diepi-11-D4c-NeuroP
|
3-((1R,2R,5S)-5-hydroxy-2-((R,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-3-oxocyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010197
|
ent-4,11-diepi-11-D4t-NeuroP
|
3-((1S,2S,5S)-5-hydroxy-2-((R,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-3-oxocyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010324
|
ent-4,11-diepi-11-E4c-NeuroP
|
3-((1R,2R,3R)-3-hydroxy-2-((R,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-5-oxocyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010325
|
ent-4,11-diepi-11-E4t-NeuroP
|
3-((1S,2S,3R)-3-hydroxy-2-((R,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-5-oxocyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010148
|
ent-4,7-diepi-4-D4c-NeuroP
|
(S,E)-4-hydroxy-6-((1R,2R,5R)-5-hydroxy-3-oxo-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010149
|
ent-4,7-diepi-4-D4t-NeuroP
|
(S,E)-4-hydroxy-6-((1S,2S,5R)-5-hydroxy-3-oxo-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010276
|
ent-4,7-diepi-4-E4c-NeuroP
|
(S,E)-4-hydroxy-6-((1R,2R,3S)-3-hydroxy-5-oxo-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010277
|
ent-4,7-diepi-4-E4t-NeuroP
|
(S,E)-4-hydroxy-6-((1S,2S,3S)-3-hydroxy-5-oxo-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010142
|
ent-4-D4c-NeuroP
|
(R,E)-4-hydroxy-6-((1S,2R,5R)-5-hydroxy-3-oxo-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010139
|
ent-4-D4t-NeuroP
|
(R,E)-4-hydroxy-6-((1R,2S,5R)-5-hydroxy-3-oxo-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010270
|
ent-4-E4c-NeuroP
|
(R,E)-4-hydroxy-6-((1S,2R,3S)-3-hydroxy-5-oxo-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010267
|
ent-4-E4t-NeuroP
|
(R,E)-4-hydroxy-6-((1R,2S,3S)-3-hydroxy-5-oxo-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010188
|
ent-4-epi-11-D4c-NeuroP
|
3-((1R,2R,5R)-5-hydroxy-2-((R,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-3-oxocyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010189
|
ent-4-epi-11-D4t-NeuroP
|
3-((1S,2S,5R)-5-hydroxy-2-((R,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-3-oxocyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010316
|
ent-4-epi-11-E4c-NeuroP
|
3-((1R,2R,3S)-3-hydroxy-2-((R,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-5-oxocyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010317
|
ent-4-epi-11-E4t-NeuroP
|
3-((1S,2S,3S)-3-hydroxy-2-((R,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-5-oxocyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010150
|
ent-4-epi-4-D4c-NeuroP
|
(S,E)-4-hydroxy-6-((1S,2R,5R)-5-hydroxy-3-oxo-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010147
|
ent-4-epi-4-D4t-NeuroP
|
(S,E)-4-hydroxy-6-((1R,2S,5R)-5-hydroxy-3-oxo-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010278
|
ent-4-epi-4-E4c-NeuroP
|
(S,E)-4-hydroxy-6-((1S,2R,3S)-3-hydroxy-5-oxo-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010275
|
ent-4-epi-4-E4t-NeuroP
|
(S,E)-4-hydroxy-6-((1R,2S,3S)-3-hydroxy-5-oxo-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010164
|
ent-7,10-diepi-7-D4c-NeuroP
|
(S,4Z,8E)-7-hydroxy-9-((1R,2R,5R)-5-hydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)-3-oxocyclopentyl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010165
|
ent-7,10-diepi-7-D4t-NeuroP
|
(S,4Z,8E)-7-hydroxy-9-((1S,2S,5R)-5-hydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)-3-oxocyclopentyl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010292
|
ent-7,10-diepi-7-E4c-NeuroP
|
(S,4Z,8E)-7-hydroxy-9-((1R,2R,3S)-3-hydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)-5-oxocyclopentyl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010293
|
ent-7,10-diepi-7-E4t-NeuroP
|
(S,4Z,8E)-7-hydroxy-9-((1S,2S,3S)-3-hydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)-5-oxocyclopentyl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010224
|
ent-7,14-diepi-14-D4c-NeuroP
|
(Z)-6-((1R,2R,5R)-5-hydroxy-2-((S,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-3-oxocyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010225
|
ent-7,14-diepi-14-D4t-NeuroP
|
(Z)-6-((1S,2S,5R)-5-hydroxy-2-((S,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-3-oxocyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010352
|
ent-7,14-diepi-14-E4c-NeuroP
|
(Z)-6-((1R,2R,3S)-3-hydroxy-2-((S,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-5-oxocyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010353
|
ent-7,14-diepi-14-E4t-NeuroP
|
(Z)-6-((1S,2S,3S)-3-hydroxy-2-((S,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-5-oxocyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010158
|
ent-7-D4c-NeuroP
|
(R,4Z,8E)-7-hydroxy-9-((1S,2R,5R)-5-hydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)-3-oxocyclopentyl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010155
|
ent-7-D4t-NeuroP
|
(R,4Z,8E)-7-hydroxy-9-((1R,2S,5R)-5-hydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)-3-oxocyclopentyl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010286
|
ent-7-E4c-NeuroP
|
(R,4Z,8E)-7-hydroxy-9-((1S,2R,3S)-3-hydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)-5-oxocyclopentyl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010283
|
ent-7-E4t-NeuroP
|
(R,4Z,8E)-7-hydroxy-9-((1R,2S,3S)-3-hydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)-5-oxocyclopentyl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010220
|
ent-7-epi-14-D4c-NeuroP
|
(Z)-6-((1R,2R,5R)-5-hydroxy-2-((R,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-3-oxocyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010221
|
ent-7-epi-14-D4t-NeuroP
|
(Z)-6-((1S,2S,5R)-5-hydroxy-2-((R,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-3-oxocyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010348
|
ent-7-epi-14-E4c-NeuroP
|
(Z)-6-((1R,2R,3S)-3-hydroxy-2-((R,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-5-oxocyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010349
|
ent-7-epi-14-E4t-NeuroP
|
(Z)-6-((1S,2S,3S)-3-hydroxy-2-((R,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-5-oxocyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|
|
LMFA04010140
|
ent-7-epi-4-D4c-NeuroP
|
(R,E)-4-hydroxy-6-((1R,2R,5R)-5-hydroxy-3-oxo-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
376.22
|
C22H32O5
|